539 related articles for article (PubMed ID: 35913427)
21. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
22. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
23. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
24. YAP and WWTR1: New targets for skin cancer treatment.
Andl T; Zhou L; Yang K; Kadekaro AL; Zhang Y
Cancer Lett; 2017 Jun; 396():30-41. PubMed ID: 28279717
[TBL] [Abstract][Full Text] [Related]
25. Recent insight into the role and therapeutic potential of YAP/TAZ in gastrointestinal cancers.
Wang Y; Chen H; Yu J; Kang W; To KF
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188787. PubMed ID: 36041574
[TBL] [Abstract][Full Text] [Related]
26. The emerging roles of YAP and TAZ in cancer.
Moroishi T; Hansen CG; Guan KL
Nat Rev Cancer; 2015 Feb; 15(2):73-79. PubMed ID: 25592648
[TBL] [Abstract][Full Text] [Related]
27. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
28. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
29. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
30. Fingolimod exerts
Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
[TBL] [Abstract][Full Text] [Related]
31. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases.
Li R; Huang W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675179
[TBL] [Abstract][Full Text] [Related]
32. YAP and TAZ are essential for basal and squamous cell carcinoma initiation.
Debaugnies M; Sánchez-Danés A; Rorive S; Raphaël M; Liagre M; Parent MA; Brisebarre A; Salmon I; Blanpain C
EMBO Rep; 2018 Jul; 19(7):. PubMed ID: 29875149
[TBL] [Abstract][Full Text] [Related]
33. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
[TBL] [Abstract][Full Text] [Related]
34. The novel role of Hippo-YAP/TAZ in immunity at the mammalian maternal-fetal interface: Opportunities, challenges.
Huang Z; Zhou J; Leung WT; Gober HJ; Pan X; Li C; Li L; Wang L
Biomed Pharmacother; 2020 Jun; 126():110061. PubMed ID: 32145593
[TBL] [Abstract][Full Text] [Related]
35. α-Catenin levels determine direction of YAP/TAZ response to autophagy perturbation.
Pavel M; Park SJ; Frake RA; Son SM; Manni MM; Bento CF; Renna M; Ricketts T; Menzies FM; Tanasa R; Rubinsztein DC
Nat Commun; 2021 Mar; 12(1):1703. PubMed ID: 33731717
[TBL] [Abstract][Full Text] [Related]
36. SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.
Weiler SME; Bissinger M; Rose F; von Bubnoff F; Lutz T; Ori A; Schirmacher P; Breuhahn K
Cancer Lett; 2024 Mar; 584():216637. PubMed ID: 38242197
[TBL] [Abstract][Full Text] [Related]
37. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy.
Thompson BJ
Bioessays; 2020 May; 42(5):e1900162. PubMed ID: 32128850
[TBL] [Abstract][Full Text] [Related]
38. Tolfenamic acid negatively regulates YAP and TAZ expression in human cancer cells.
Kim I; Lertpatipanpong P; Yoon Y; Lee J; Hong Y; Boonruang K; Ryu J; Baek SJ
Biochim Biophys Acta Mol Cell Res; 2023 Dec; 1870(8):119556. PubMed ID: 37544381
[TBL] [Abstract][Full Text] [Related]
39. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.
Moya IM; Halder G
Nat Rev Mol Cell Biol; 2019 Apr; 20(4):211-226. PubMed ID: 30546055
[TBL] [Abstract][Full Text] [Related]
40. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.
Cunningham R; Hansen CG
Clin Sci (Lond); 2022 Feb; 136(3):197-222. PubMed ID: 35119068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
